Can recreational doses of THC produce significant dopamine release in the human striatum?

NeuroImage

Volumn 48, Issue 1, 2009, Pages 186-190

  Stokes, Paul R A ^a   Mehta, Mitul A ^a,b   Curran, H Valerie ^c   Breen, Gerome ^b   Grasby, Paul M ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

11C raclopride; Cannabis; Dopamine; PET; Schizophrenia; THC

Indexed keywords

CANNABIS; DOPAMINE; DRONABINOL; PLACEBO; RACLOPRIDE C 11;

ADULT; ARTICLE; CORPUS STRIATUM; DOPAMINE RELEASE; DRUG ACTIVITY; DRUG BLOOD LEVEL; FEMALE; HUMAN; HUMAN EXPERIMENT; IMAGE ANALYSIS; IN VIVO STUDY; MALE; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; VOLUNTEER;

ADULT; ANALYSIS OF VARIANCE; CORPUS STRIATUM; DOPAMINE; FEMALE; HUMANS; MALE; POSITRON-EMISSION TOMOGRAPHY; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTROPIC DRUGS; RACLOPRIDE; TETRAHYDROCANNABINOL;

EID: 67949121758     PISSN: 10538119     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2009.06.029     Document Type: Article

References (24)

1. Abi-Dargham A., Rodenhiser J., Printz D., Zea-Ponce Y., Gil R., Kegeles L.S., Weiss R., Cooper T.B., Mann J.J., Van Heertum R.L., Gorman J.M., and Laruelle M. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 8104-8109
2. Bossong M.G., van Berckel B.N., Boellaard R., Zuurman L., Schuit R.C., Windhorst A.D., van Gerven J.M., Ramsey N.F., Lammertsma A.A., and Kahn R.S. Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology 34 (2009) 759-766
3. Breier A., Su T.P., Saunders R., Carson R.E., Kolachana B.S., de Bartolomeis A., Weinberger D.R., Weisenfeld N., Malhotra A.K., Eckelman W.C., and Pickar D. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 2569-2574
4. Breier A., Adler C.M., Weisenfeld N., Su T.P., Elman I., Picken L., Malhotra A.K., and Pickar D. Effects of NMDA antagonism on striatal dopamine release in healthy subjects: application of a novel PET approach. Synapse 29 (1998) 142-147
5. Carson R.E., Breier A., de Bartolomeis A., Saunders R.C., Su T.P., Schmall B., Der M.G., Pickar D., and Eckelman W.C. Quantification of amphetamine-induced changes in [11C]raclopride binding with continuous infusion. J. Cereb. Blood Flow Metab. 17 (1997) 437-447
6. Caspi A., Moffitt T.E., Cannon M., McClay J., Murray R., Harrington H., Taylor A., Arseneault L., Williams B., Braithwaite A., Poulton R., and Craig I.W. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol. Psychiatry 57 (2005) 1117-1127
7. Chawla S. World Drug Report 2006 (2006), United Nations Office on Drugs and Crime, New York City, New York, USA
8. Cheer J.F., Wassum K.M., Heien M.L., Phillips P.E., and Wightman R.M. Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake rats. J. Neurosci. 24 (2004) 4393-4400
9. Curran H.V., Brignell C., Fletcher S., Middleton P., and Henry J. Cognitive and subjective dose-response effects of acute oral delta 9-tetrahydrocannabinol (THC) in infrequent cannabis users. Psychopharmacology (Berl) 164 (2002) 61-70
10. Gogos J.A., Morgan M., Luine V., Santha M., Ogawa S., Pfaff D., and Karayiorgou M. Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 9991-9996
11. Innis R.B., Cunningham V.J., Delforge J., Fujita M., Gjedde A., Gunn R.N., Holden J., Houle S., Huang S.C., Ichise M., Iida H., Ito H., Kimura Y., Koeppe R.A., Knudsen G.M., Knuuti J., Lammertsma A.A., Laruelle M., Logan J., Maguire R.P., Mintun M.A., Morris E.D., Parsey R., Price J.C., Slifstein M., Sossi V., Suhara T., Votaw J.R., Wong D.F., and Carson R.E. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J. Cereb. Blood Flow Metab. 27 (2007) 1533-1539
12. Laruelle M., Abi-Dargham A., van Dyck C.H., Gil R., D'Souza C.D., Erdos J., McCance E., Rosenblatt W., Fingado C., Zoghbi S.S., Baldwin R.M., Seibyl J.P., Krystal J.H., Charney D.S., and Innis R.B. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 9235-9240
13. Martinez D., Slifstein M., Broft A., Mawlawi O., Hwang D.R., Huang Y., Cooper T., Kegeles L., Zarahn E., Abi-Dargham A., Haber S.N., and Laruelle M. Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum. J. Cereb. Blood Flow Metab. 23 (2003) 285-300
14. Mason O.J., Morgan C.J., Stefanovic A., and Curran H.V. The Psychotomimetic States Inventory (PSI): measuring psychotic-type experiences from ketamine and cannabis. Schizophr. Res. 103 (2008) 138-142
15. McGowan S., Lawrence A.D., Sales T., Quested D., and Grasby P. Presynaptic dopaminergic dysfunction in schizophrenia: a positron emission tomographic [18F]fluorodopa study. Arch. Gen. Psychiatry 61 (2004) 134-142
16. Montgomery A.J., Thielemans K., Mehta M.A., Turkheimer F., Mustafovic S., and Grasby P.M. Correction of head movement on PET studies: comparison of methods. J. Nucl. Med. 47 (2006) 1936-1944
17. Moore T.H., Zammit S., Lingford-Hughes A., Barnes T.R., Jones P.B., Burke M., and Lewis G. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370 (2007) 319-328
18. Smart R., and Adlaf E.M. THC consumption among students: its estimation and log-normality. Br. J. Addict. 81 (1986) 59-63
19. Tanda G., Pontieri F.E., and Di Chiara G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 276 (1997) 2048-2050
20. Turkheimer F.E., Brett M., Visvikis D., and Cunningham V.J. Multiresolution analysis of emission tomography images in the wavelet domain. J. Cereb. Blood Flow Metab. 19 (1999) 1189-1208
21. Volkow N.D., Wang G.J., Fowler J.S., Logan J., Franceschi D., Maynard L., Ding Y.S., Gatley S.J., Gifford A., Zhu W., and Swanson J.M. Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implications. Synapse 43 (2002) 181-187
22. Voruganti L.N., Slomka P., Zabel P., Mattar A., and Awad A.G. Cannabis induced dopamine release: an in-vivo SPECT study. Psychiatry Res. 107 (2001) 173-177
23. Watabe H., Endres C.J., Breier A., Schmall B., Eckelman W.C., and Carson R.E. Measurement of dopamine release with continuous infusion of [11C]raclopride: optimization and signal-to-noise considerations. J. Nucl. Med. 41 (2000) 522-530
24. Wilson R.I., and Nicoll R.A. Endocannabinoid signaling in the brain. Science 296 (2002) 678-682